Cancer therapy specialist Helsinn Group reported that anamorelin, its once-daily ghrelin receptor agonist for the common wasting disease cachexia significantly increased lean body mass (LBM) compared to placebo in two phase III trials in non-small-cell lung cancer (NSCLC) patients.